Ioana R Preston

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. pmc Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension
    Ioana R Preston
    Tupper Research Institute and Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 304:L678-88. 2013
  2. doi request reprint Properly diagnosing pulmonary arterial hypertension
    Ioana R Preston
    Pulmonary and Critical Care Division, New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 111:2C-9C. 2013
  3. ncbi request reprint Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides
    M Kathryn Steiner
    Pulmonary, Critical Care and Sleep Divisions, Tufts New England Medical Center, Boston, Massachussets, USA
    Curr Opin Pharmacol 5:245-50. 2005
  4. pmc Serotonylated fibronectin is elevated in pulmonary hypertension
    Lin Wei
    Tufts University School of Medicine, Tufts Medical Center, Tupper Research Institute, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 302:L1273-9. 2012
  5. ncbi request reprint Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension
    Ioana R Preston
    Department of Pulmonary, Critical Care and Sleep, Tufts New England Medical Center, 750 Washington Street, Box 257, Boston, MA 0211, USA
    Respir Med 99:1501-10. 2005
  6. ncbi request reprint Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 290:L367-74. 2006
  7. ncbi request reprint Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study
    M Kathryn Steiner
    Tufts New England Medical Center, Boston, MA, USA
    Chest 130:1471-80. 2006
  8. pmc Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
    M Kathryn Steiner
    Pulmonary Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Vasc Health Risk Manag 4:943-52. 2008
  9. ncbi request reprint Retinoids and pulmonary hypertension
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts New England Medical Center, Tupper Research Institute, Boston, Mass, USA
    Circulation 111:782-90. 2005
  10. ncbi request reprint Postoperative pulmonary hypertension: etiology and treatment of a dangerous complication
    Nicholas S Hill
    Division of Pulmonary Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Respir Care 54:958-68. 2009

Collaborators

Detail Information

Publications17

  1. pmc Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension
    Ioana R Preston
    Tupper Research Institute and Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 304:L678-88. 2013
    ..These data suggest that MR is involved in the pathogenesis of PH via effects on PASMCs and that MR antagonism may represent a novel therapeutic target for this disease...
  2. doi request reprint Properly diagnosing pulmonary arterial hypertension
    Ioana R Preston
    Pulmonary and Critical Care Division, New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA
    Am J Cardiol 111:2C-9C. 2013
    ....
  3. ncbi request reprint Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides
    M Kathryn Steiner
    Pulmonary, Critical Care and Sleep Divisions, Tufts New England Medical Center, Boston, Massachussets, USA
    Curr Opin Pharmacol 5:245-50. 2005
    ..Further, the combination of PDE5 inhibitors and agents that increase cGMP or cAMP also yields additive beneficial effects on pulmonary hemodynamics in patients with pulmonary arterial hypertension...
  4. pmc Serotonylated fibronectin is elevated in pulmonary hypertension
    Lin Wei
    Tufts University School of Medicine, Tufts Medical Center, Tupper Research Institute, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 302:L1273-9. 2012
    ..77). TGase-bound FN also was increased in experimental PH. We conclude that increased serotonylation of FN occurs in human and experimental PH and may provide a biomarker for the disease...
  5. ncbi request reprint Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension
    Ioana R Preston
    Department of Pulmonary, Critical Care and Sleep, Tufts New England Medical Center, 750 Washington Street, Box 257, Boston, MA 0211, USA
    Respir Med 99:1501-10. 2005
    ..Long-term therapy of pulmonary hypertension with sildenafil alone or in combination with other agents appears to be safe and well tolerated...
  6. ncbi request reprint Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
    Am J Physiol Lung Cell Mol Physiol 290:L367-74. 2006
    ..We conclude that 12-LO and its product, 12(S)-HETE, are important intermediates in hypoxia-induced pulmonary artery SMC proliferation and may participate in hypoxia-induced pulmonary hypertension...
  7. ncbi request reprint Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study
    M Kathryn Steiner
    Tufts New England Medical Center, Boston, MA, USA
    Chest 130:1471-80. 2006
    ..We assessed the efficacy of bosentan in transitioning from prostacyclin infusions in patients with pulmonary arterial hypertension (PAH)...
  8. pmc Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
    M Kathryn Steiner
    Pulmonary Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Vasc Health Risk Manag 4:943-52. 2008
    ..Ongoing and forthcoming randomized trials are also highlighted including the approach of combining this class of drugs with other drugs that target different cellular pathways believed to be etiologically important in PAH...
  9. ncbi request reprint Retinoids and pulmonary hypertension
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts New England Medical Center, Tupper Research Institute, Boston, Mass, USA
    Circulation 111:782-90. 2005
    ..Thus, the present study examined retinoid levels in plasma of patients with idiopathic pulmonary arterial hypertension and the effects of retinoic acid on human pulmonary artery smooth muscle cell growth...
  10. ncbi request reprint Postoperative pulmonary hypertension: etiology and treatment of a dangerous complication
    Nicholas S Hill
    Division of Pulmonary Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Respir Care 54:958-68. 2009
    ..Better understanding of the pathophysiology of right heart failure and controlled trials testing therapeutic approaches are needed if we are to make progress in treating this heretofore highly mortal condition...
  11. ncbi request reprint Clinical perspective of hypoxia-mediated pulmonary hypertension
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Antioxid Redox Signal 9:711-21. 2007
    ..The purpose of this review is briefly to (a) discuss the mechanisms of hypoxic pulmonary hypertension as it pertains to certain disease states, and (b) examine the pathways that have potential therapeutic applications for this condition...
  12. pmc Differences between basal lung levels of select eicosanoids in rat and mouse
    Kristen D Sagliani
    Pulmonary, Critical Care and Sleep Division, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA
    Pulm Circ 3:82-8. 2013
    ....
  13. pmc Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
    Ioana R Preston
    Pulmonary, Critical Care and Sleep Division, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA
    Pulm Circ 3:68-73. 2013
    ..Exposure of HFpEF patients to inhaled vasodilators worsens the PAWP without hemodynamic benefit...
  14. doi request reprint Patients with pulmonary arterial hypertension in clinical trials: who are they?
    Nicholas S Hill
    Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, 800 Washington Street, 257, Boston, MA 02111, USA
    Proc Am Thorac Soc 5:603-9. 2008
    ..These characteristics must be carefully considered when applying the findings of pulmonary hypertension trials in clinical practice...
  15. ncbi request reprint Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension
    Ioana R Preston
    Department of Pulmonary, Critical Care and Sleep Medicine, Tufts New England Medical Center, 750 Washington Street, Box 257, Boston, MA 02111, USA
    Exp Biol Med (Maywood) 229:920-5. 2004
    ..During chronic hypoxia, sildenafil normalizes RVSP, but in the doses used, sildenafil has no effect on RV hypertrophy or pulmonary vascular remodeling...
  16. doi request reprint Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications
    Adam P McGraw
    Molecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Street, Boston, MA, USA
    Curr Atheroscler Rep 15:340. 2013
    ....
  17. pmc Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
    Kari E Roberts
    Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
    Drug Des Devel Ther 3:111-8. 2009
    ..Ongoing and forthcoming randomized trials are also highlighted including the application of bosentan in combination with other PAH therapies...